BIOMARKERS FOR PREDICTING CYTOKIN RELEASE SYNDROME

DE602016094907T2Active Publication Date: 2026-03-11NOVARTIS AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Filing Date
2016-09-02
Publication Date
2026-03-11

AI Technical Summary

Technical Problem

There is a need for methods and biomarkers to predict a patient's risk of developing severe cytokine release syndrome (CRS) associated with CAR T cell therapy, which is a potentially life-threatening adverse side effect.

Method used

The method involves evaluating the level or activity of biomarkers such as soluble gp130 (sgp130) or soluble IL6 receptor (sIL6R) in a subject to determine the risk of developing severe CRS, allowing for early intervention and potential adjustments to treatment.

Benefits of technology

This approach enables early and accurate identification of subjects at high risk for severe CRS, enabling interventions to reduce morbidity and mortality, and is more sensitive and specific than current treatment modalities.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.